Chemours Company (the) · NYSE:CC
Chemours Company (the) — Investor Presentation (November 2015)
19 slides from Chemours Company (the)'s investor presentation, Nov 30, 2015
Slide 1: The Chemours Company Investor Presentation December 2015
The Chemours Company Investor Presentation December 2015 Exhibit 99.1
Slide 2: Forward-looking statements and non-GAAP disclaimer
This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipat
Slide 3: The Chemours Company at a Glance
The Chemours Company at a Glance Chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries #1 producer in Americas sodium cyanide #1 in US Northeast sulfuric acid regeneration #2 in US Gulf Coast sulfuric acid regeneration LTM Sales:$5,906 LTM Adj. EBITDA
Slide 4: Titanium Technologies Business Overview
Global leader in TiO2 with production capacity of 1.2 million metric tons(1) 4 TiO2 plants with 7 production lines(1) Packaging facility at Kallo, Belgium Mineral sands mine at Starke, FL Industry-leading manufacturing cost position Unique chloride technology Feedstock flexibility Strong brand reput
Slide 5: Fluoroproducts Business Overview
Supplies products for high performance applications across broad array of industries #1 in Fluoroproducts globally Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties Key Brands include Teflon®, Freon®,
Slide 6: Chemical Solutions Overview
Diverse portfolio of industrial businesses primarily operating in the Americas Unmatched reputation for safety, reliability and stewardship 14 production facilities located in North America and one located in the U.K. Chemical Solutions Overview Source:Company filings and data Reflects full year 201
Slide 7: Chemours Transformation Plan
Chemours Transformation Plan
Slide 8: Transformation Plan Priorities
Transformation Plan Priorities Refocus Investments Concentrate capital spending on investable business portfolio Invest in the next increment of Opteon™ and Cyanides capacity Rationalize annual capital spending to ~$350M in 2017 Reduce Costs Target cost reductions of ~$100M in second half of 2015 Ta
Slide 9: Transformation Plan Priorities: Reduce Costs
Transformation Plan Priorities: Reduce Costs Cost Reduction Activities Targeting ~$450 Million in Cumulative Savings $M represents millions ~$300M ~$450M $350M Incremental to 2015
Slide 10: Transformation Plan Priorities: Optimize The Portfolio
Transformation Plan Priorities: Optimize The Portfolio Progress on Strategic Review of Chemical Solutions Retain Under Review Sell Shutdown Cyanides Sulfur Products Aniline Clean & Disinfect Chemicals Methyl- amines Reactive Metals 9
Slide 11: Transformation Plan Priorities: Grow Market Positions (Opteon)
Transformation Plan Priorities: Grow Market Positions Opteon™ YF Next Gen Gas for MAC HFO-1336(Z) Next Gen Liquids for Foams, Centrifugal Chillers, Organic Rankine Cycles, High Temp Heat Pumps Opteon™ YF blends Next Gen Gas for Commercial Refrigeration, Residential/Light Commercial A/C, Chillers, Hi
Slide 12: Grow Market Positions: Altamira & Cyanides Expansions
Transformation Plan Priorities: Grow Market Positions Altamira & Cyanides Expansions – On Track 200,000 metric ton capacity, one of the lowest cost production lines Production scheduled to start up in mid-2016 Adds low-cost capacity and provides incremental fixed cost leverage Expected to deliver ~$
Slide 13: Refocus Investments and Enhance Financial Position
Transformation Plan Priorities: Refocus Investments and Enhance Financial Position Path Toward Improving Free Cash Flow $500M Adjusted EBITDA improvement $140M gross sale proceeds from Aniline Chemical Solutions strategic review could yield additional proceeds in 2016 Working capital Second half sea
Slide 14: Chemours Transformation Plan Results
Chemours Transformation Plan Results Global leader in titanium dioxide and fluoroproducts Proprietary products and brands with above-average growth Low cost assets provide advantaged position across the cycle Global Market Leader with Premier Cost Position Titanium Technologies – Altamira expansion
Slide 15: ©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks
©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company
Slide 16: Appendix
Appendix
Slide 17: Reconciliation of Adjusted EBITDA to Net (Loss) Income
Reconciliation of Adjusted EBITDA to Net (Loss) Income Three Months Ended Nine Months Ended Last Twelve Months September 30, September 30, September 30, ($ in millions) 2015 2014 2015 2014 2015 Total Adjusted EBITDA $169 $235 $441 $671 $646 Interest (51) - (79) - (79) Depreciation and amortization (
Slide 18: Segment Net Sales and Adjusted EBITDA
Segment Net Sales and Adjusted EBITDA Note: In September 2015, the definition of Adjusted EBITDA was updated. All prior periods have been updated to reflect the current presentation. SEGMENT NET SALES LTM 2015 3Q15 2Q15 1Q15 4Q14 Titanium Technologies 2,491 616 642 545 688 Fluoroproducts 2,290 575 5
Slide 19: ©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks
©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company